Vaxtex Cotfab Intrinsic Value
Vaxtex Cotfab (VCL) median intrinsic value is ₹2.75 from 9 valuation models (range ₹2–₹3), vs current price ₹1.10 — +150.0% upside (Trading Below Calculated Value), margin of safety 60.0%. Analyse VCL FII DII holdings to track promoter, FII and institutional holdings.
VCL Valuation Methods Summary — DCF, Graham Number & P/E
Vaxtex Cotfab intrinsic value across 9 models vs current price ₹1.10 — upside/downside and value range per method. For current market price and key ratios, visit Vaxtex Cotfab share price chart.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹3.30 | ₹2.64 - ₹3.96 | +200.0% | EPS: ₹0.30, Sector P/E: 12x |
| Book Value Method | asset | ₹2.75 | ₹2.48 - ₹3.03 | +150.0% | Book Value/Share: ₹12.22, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹2.20 | ₹1.98 - ₹2.42 | +100.0% | Revenue/Share: ₹6.11, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹2.20 | ₹1.98 - ₹2.42 | +100.0% | EBITDA: ₹2.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹2.75 | ₹2.20 - ₹3.30 | +150.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹3.30 | ₹2.97 - ₹3.63 | +200.0% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹2.40 | ₹2.16 - ₹2.64 | +118.2% | Revenue Growth: -30.0%, Adj P/E: 8.0x |
| ROE Based Valuation | profitability | ₹2.20 | ₹1.98 - ₹2.42 | +100.0% | ROE: 22.7%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹3.30 | ₹2.97 - ₹3.63 | +200.0% | EPS: ₹0.30, BVPS: ₹12.22 |
VCL Intrinsic Value vs Market Price — All Valuation Models
Vaxtex Cotfab fair value range ₹2–₹3 vs current market price ₹1.10 across 9 valuation models. Read VCL dividend growth for the complete payout history and dividend yield track record.
VCL Intrinsic Value Analysis — Undervalued or Overvalued?
Vaxtex Cotfab median intrinsic value ₹2.75, current price ₹1.10 — Trading Below Calculated Value by 150.0%, margin of safety 60.0%.
What is the intrinsic value of VCL?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Vaxtex Cotfab (VCL) is ₹2.75 (median value). With the current market price of ₹1.10, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹2.20 to ₹3.30, indicating ₹2.20 - ₹3.30.
Is VCL undervalued or overvalued?
Based on our multi-method analysis, Vaxtex Cotfab (VCL) appears to be trading below calculated value by approximately 150.0%.
VCL Financial Health — Key Ratios vs Industry Benchmarks
Vaxtex Cotfab financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 18.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 22.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 17.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.30x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
VCL Cash Flow Quality — Operating & Free Cash Flow
Vaxtex Cotfab operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹-48 Cr | ₹-48 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-11 Cr | ₹-11 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹7 Cr | ₹5 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |